NASDAQ: AMLXAmylyx Pharmaceuticals Inc Stock
$1.78-0.10 (-5.32%)
Updated Apr 25, 2024
AMLX Price
$1.78
Fair Value Price
N/A
Market Cap
$120.65M
52 Week Low
$1.76
52 Week High
$30.50
P/E
2.44x
P/B
0.28x
P/S
2.6x
PEG
0.02x
Dividend Yield
N/A
Revenue
$380.79M
Earnings
$49.27M
Gross Margin
93.3%
Operating Margin
14.26%
Profit Margin
12.9%
Debt to Equity
0.19
Operating Cash Flow
$12M
Beta
1.18
Next Earnings
Jun 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
AMLX Overview
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, for the treatment of ALS. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMLX ($1.78) is trading below its intrinsic value of $40.38, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMLX is good value based on its earnings relative to its share price (2.44x), compared to the US market average (40.97x)
P/E vs Market Valuation
AMLX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AMLX due diligence checks available for Premium users.
Be the first to know about important AMLX news, forecast changes, insider trades & much more!
AMLX News
Valuation
AMLX fair value
Fair Value of AMLX stock based on Discounted Cash Flow (DCF)
Price
$1.78
Fair Value
-$14.42
Undervalued by
112.34%
AMLX ($1.78) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.44x
Industry
15.41x
Market
40.97x
AMLX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AMLX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AMLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.28x
Industry
5.8x
AMLX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMLX price to earnings growth (PEG)
For valuing profitable companies with growth potential
AMLX is good value based... subscribe to Premium to read more.
PEG Value Valuation
AMLX's financial health
Profit margin
Revenue
$108.4M
Net Income
$4.7M
Profit Margin
4.4%
AMLX's Earnings (EBIT) of $54.30M... subscribe to Premium to read more.
Interest Coverage Financials
AMLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$517.5M
Liabilities
$84.0M
Debt to equity
0.19
AMLX's short-term assets ($464.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMLX's short-term assets ($464.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$13.6M
Investing
$20.9M
Financing
$230.0k
AMLX's operating cash flow ($11.92M)... subscribe to Premium to read more.
Debt Coverage Financials
AMLX vs Biotech Stocks
Amylyx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.